Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Rousseau B, Kempf E, Desamericq G, Boissier E, Chaubet-Houdu M, Joly C, Saldana C, Boussion H, Neuzillet C, Macquin-Mavier I, Oudard S, Salomon L, de la Taille A, Tournigand C. Rousseau B, et al. Among authors: tournigand c. Crit Rev Oncol Hematol. 2016 Nov;107:44-53. doi: 10.1016/j.critrevonc.2016.08.012. Epub 2016 Sep 1. Crit Rev Oncol Hematol. 2016. PMID: 27823651
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J; Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM, et al. Among authors: tournigand c. J Clin Oncol. 2003 Nov 1;21(21):3987-94. doi: 10.1200/JCO.2003.02.073. J Clin Oncol. 2003. PMID: 14581421 Clinical Trial.
Stage II and stage III colon cancer: treatment advances and future directions.
Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, André T, de Gramont A; GERCOR (French Oncology Research Group). Rousseau B, et al. Among authors: tournigand c. Cancer J. 2010 May-Jun;16(3):202-9. doi: 10.1097/PPO.0b013e3181ddc5bf. Cancer J. 2010. PMID: 20526097 Review.
Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.
Rousseau B, Loulergue P, Mir O, Krivine A, Kotti S, Viel E, Simon T, de Gramont A, Goldwasser F, Launay O, Tournigand C. Rousseau B, et al. Among authors: tournigand c. Ann Oncol. 2012 Feb;23(2):450-7. doi: 10.1093/annonc/mdr141. Epub 2011 May 16. Ann Oncol. 2012. PMID: 21576285 Free article. Clinical Trial.
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A. Chibaudel B, et al. Among authors: tournigand c. J Clin Oncol. 2011 Nov 1;29(31):4199-204. doi: 10.1200/JCO.2011.35.5867. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969501
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Shi Q, et al. Among authors: tournigand c. J Clin Oncol. 2015 Jan 1;33(1):22-8. doi: 10.1200/JCO.2014.56.5887. Epub 2014 Nov 10. J Clin Oncol. 2015. PMID: 25385741 Free PMC article.
State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. Neuzillet C, et al. Among authors: tournigand c. Pharmacol Ther. 2015 Nov;155:80-104. doi: 10.1016/j.pharmthera.2015.08.006. Epub 2015 Aug 20. Pharmacol Ther. 2015. PMID: 26299994 Review.
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, Mansuy L, Bastien C, de la Taille A, Boussion H, Charpy C, Jourdain A, Bléchet C, Pierron G, Gentien D, Choudat L, Tournigand C, Delattre O, Allory Y, Bourdeaut F. Calderaro J, et al. Among authors: tournigand c. Eur Urol. 2016 Jun;69(6):1055-61. doi: 10.1016/j.eururo.2015.09.027. Epub 2015 Oct 1. Eur Urol. 2016. PMID: 26433572
Cinétique du PSA comme facteur prédictif de réponse par acétate d'abiratérone chez les patients atteints d'un cancer de la prostate en phase de résistance à la castration.
Saldana C, Chaubet-Houdu M, Joly C, Charbit D, Vordos D, Vacherot F, Salomon L, Tournigand C, De la Taille A. Saldana C, et al. Among authors: tournigand c. Prog Urol. 2014 Nov;24(13):818-9. doi: 10.1016/j.purol.2014.08.078. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461604 French. No abstract available.
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A. Tournigand C, et al. Lancet Oncol. 2015 Nov;16(15):1493-1505. doi: 10.1016/S1470-2045(15)00216-8. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26474518 Clinical Trial.
235 results